EpicentRx Inc, La Jolla, California, USA.
EpicentRx Inc, La Jolla, California, USA
J Immunother Cancer. 2024 Oct 26;12(10):e009613. doi: 10.1136/jitc-2024-009613.
At the ASCO 2024 meeting, Anthony P Conley, coauthor on this editorial, presented promising data from the phase 1/2 clinical trial called BETA PRIME (ClinicalTrials.gov NCT04673942) with AdAPT-001 plus a checkpoint inhibitor (CI). All participants gave informed consent to participate in BETA PRIME before taking part. AdAPT-001 is an oncolytic adenovirus that expresses a transforming growth factor beta (TGF-β) trap to neutralize active TGF-β. This editorial proposes that the TGF-β trap of AdAPT-001 reverses the immunosuppressive environment of tumor cells, and thus makes these tumors susceptible to CIs like the anti-PD-1 agent, nivolumab, and potentially other therapies as well.
在 2024 年 ASCO 会议上，该社论的合著者 Anthony P Conley 展示了名为 BETA PRIME（ClinicalTrials.gov NCT04673942）的 1/2 期临床试验的有希望的数据，该试验使用了 AdAPT-001 加检查点抑制剂（CI）。所有参与者在参与 BETA PRIME 之前都已同意知情参与。AdAPT-001 是一种表达转化生长因子-β（TGF-β）陷阱以中和活性 TGF-β 的溶瘤腺病毒。本社论认为，AdAPT-001 的 TGF-β 陷阱逆转了肿瘤细胞的免疫抑制环境，从而使这些肿瘤对 PD-1 抑制剂nivolumab 等 CI 以及潜在的其他疗法敏感。
